Methylomics is a start-up company that applies state of the art methylation sequencing technology (MeD-seq) for diagnosis and classification of cancer as well as disease progression and therapy response monitoring. With a multidisciplinary team of top scientists, we construct a DNA methylation atlas of different tissues and associated cancers. Methylomics developed in-house bioinformatic algorithms to rapidly discover differentially methylated regions for specific cancer types. We aim to generate a database that can be used for the diagnosis, as well as the determination of the origin, of all cancer types.
In addition to marker discovery and direct classification of cancers we use the marker profiles generated by our MeD-seq technology as a basis for the development of fast and low-cost methylation assays. Because of our streamlined bioinformatic process to select these markers and design assays, Methylomics is rapidly expanding its pipeline, now including cancers of the colorectal region, skin, head & neck, anus, and uro-genital zone (e.g., cervical, ovarian, vulva and endometrial cancers).
Methylomics discovered two proprietary pan-gynecological markers and developed a MeD-Scan assay for the rapid detection of all types of gynecological cancer. Three validation studies, showing the remarkably high sensitivity of this MeD-Scan assay, will be published in Q1 2024, along with the patent application for these markers.
A novel method to detect DNA methylation genome wide
Developed by the founders Methylomics, Methylated DNA Sequencing (MeD-seq) offers a cutting-edge approach for genome-wide methylation profiling. The distinguishing feature of our sequencing technology is the utilization of a methylation-dependent restriction enzyme. When this enzyme digests DNA, it generates small fragments containing methylated CpG sites. These fragments are then isolated and prepared for Next Generation Sequencing. What sets MeD-seq apart is its ability to explore nearly half of the CpG sites in the human genome. Unlike alternative methods, like bisulfite sequencing and array platforms, MeD-seq eliminates the need for DNA bisulfite conversion, facilitating unbiased genome-wide DNA methylation profiling. Because of the omission of the DNA-damaging bisulfite conversion step, the minimal required DNA input is significantly lower compared to other methods. This property makes MeD-seq highly compatible with applications such as Laser Capture Microdissection (LCM), liquid biopsy samples (such as cell-free DNA), and small populations of FACS-sorted cell types. Given that MeD-seq exclusively sequences methylated DNA, it's been demonstrated to yield comprehensive DNA methylation data at significantly lower costs when compared to alternative techniques.
The MeD-seq technology can be used for the diagnosis of cancers and other diseases, as a marker discovery tool and basis for the development of rapid diagnostic assays, and for the monitoring of treatment outcomes.
Profiling DNA Methylation genome wide
Transformation of healthy cells into cancer cells coincides with massive changes in genome wide DNA methylation. MeD-seq is applied to detect DNA methylation profiles of healthy tissues and (pre-) cancerous lesions and has already been compared to other techniques.read more
Methylation marker discovery for specific cancers and cancer subgroups
With the sequencing data from MeD-seq we construct genome-wide DNA methylation profiles for normal and diseased tissue types to develop cancer detection markers.read more
Target DNA enrichment using Laser Capture Microdissection
Laser Capture Microdissection (LCM) is an accurate method to select and isolate specific cell populations from heterogeneous archived paraffine embedded tissue for further downstream genome-wide DNA methylation profiling.read more
MeD-seq: Pushing down the limit of DNA required
MeD-seq requires a relatively low amount of DNA, making it compatible with a range of applications like cell free DNA and Laser Capture Micro dissected DNA samples. Efforts are undertaken to push MeD-seq towards the single cell level.